Premium
Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia
Author(s) -
Karhapää Pauli,
Uusitupa Matti,
Voutilainen Erkki,
Laakso Markku
Publication year - 1992
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1992.200
Subject(s) - bezafibrate , medicine , endocrinology , triglyceride , insulin , hyperlipidemia , glucose clamp technique , insulin resistance , basal (medicine) , chemistry , diabetes mellitus , insulin sensitivity , cholesterol
To investigate whether the lowering of triglyceride levels has beneficial effects on glucose metabolism, we studied 13 nondiabetic men with combined hyperlipidemia (phenotype IIB) before and after 2 months of treatment with a slow‐release formulation of bezafibrate (400 mg daily). The rates of whole body glucose disposal were quantitated by the euglycemic hyperinsulinemic clamp technique (insulin infusion rate of 80 mU/m 2 /min). In an oral glucose tolerance test, fasting glucose level decreased slightly (5.0 ± 0.2 versus 4.8 ± 0.2 mmol/L; p < 0.05) during bezafibrate treatment. Glucose and insulin levels after an oral glucose load remained unchanged. Rates of whole body glucose disposal did not change during bezafibrate treatment (39.5 ± 3.3 µmol/kg/min before treatment versus 40.6 ± 2.7 µmol/kg/min after treatment; difference not significant). Basal hepatic glucose output also remained unchanged (8.2 ± 0.2 µmol/kg/min before treatment versus 8.3 ± 0.2 µmol/kg/min after treatment; difference not significant). Our findings show that bezafibrate has a triglyceride‐lowering effect without any significant influence on insulin sensitivity. Clinical Pharmacology and Therapeutics (1992) 52 , 620–626; doi: 10.1038/clpt.1992.200